The Valley Desk

NCT01708954 · Interventional trial

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Overall registry status Active not recruiting

Phase 2

Conditions Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov